Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Journal article
Hayward G. et al, (2024), Journal of Infection, 88
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Journal article
Standing JF. et al, (2024), Nature communications, 15
Platform adaptive trial of novel antivirals for early treatment of COVID-19 in the community (PANORAMIC): Protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
Journal article
Gbinigie O. et al, (2023), BMJ Open, 13
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Journal article
Butler CC. et al, (2023), The Lancet, 401, 281 - 293
C-reactive protein point-of-care testing and complementary strategies to improve antibiotic stewardship in children with acute respiratory infections in primary care
Journal article
Staiano A. et al, (2023), Frontiers in Pediatrics, 11
Guidance on C-reactive protein point-of-care testing and complementary strategies to improve antibiotic prescribing for adults with lower respiratory tract infections in primary care
Journal article
Van Hecke O. et al, (2023), Frontiers in Medicine, 10
Inhaled Budesonide for COVID-19 in People at Higher Risk of Complications in the Community: The UK National Community Randomi
Conference paper
Hobbs R. et al, (2023), Annals of family medicine
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Journal article
Dorward J. et al, (2022), British Journal of General Practice, 72, E446 - E455
Point-of-care diagnostic technology in paediatric ambulatory care: a qualitative interview study of English clinicians and stakeholders
Journal article
Raymond ME. et al, (2022), BMJ open, 12
Primary care preparedness for the SARS-CoV-2 pandemic: a survey of NHS GPs
Journal article
Pilbeam C. et al, (2022), Family practice, 39, 332 - 339
Author response
Journal article
Borek A. et al, (2022), The British journal of general practice : the journal of the Royal College of General Practitioners, 72
Role of locum GPs in antibiotic prescribing and stewardship: a mixed-methods study
Journal article
Borek AJ. et al, (2022), The British journal of general practice : the journal of the Royal College of General Practitioners, 72, e118 - e127
P47 Infographics about antibiotics: making facts accessible
Conference paper
van Hecke O. et al, (2022), JAC-ANTIMICROBIAL RESISTANCE, 4
Exploring primary care clinicians’ views about how best to implement a potential trial around point-of-care tests for common infections in south africa
Journal article
Epps A. et al, (2021), Diagnostics, 11
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Journal article
Yu LM. et al, (2021), The Lancet, 398, 843 - 855
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Journal article
Butler CC. et al, (2021), The Lancet, 397, 1063 - 1074
Association Between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients With Hypertension: An Observational Cohort Study
Journal article
Sheppard JP. et al, (2021), Hypertension (Dallas, Tex. : 1979), 77, 846 - 855
Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Preprint
PRINCIPLE Trial Collaborative Group None. et al, (2021)
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Journal article
PRINCIPLE Collaborative Group None. et al, (2021)